Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Total Non-Current Liabilities (2019 - 2021)

Pliant Therapeutics has reported Total Non-Current Liabilities over the past 3 years, most recently at $22.2 million for Q4 2021.

  • Quarterly Total Non-Current Liabilities rose 91.02% to $22.2 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $22.2 million through Dec 2021, up 91.02% year-over-year, with the annual reading at $22.2 million for FY2021, 91.02% up from the prior year.
  • Total Non-Current Liabilities was $22.2 million for Q4 2021 at Pliant Therapeutics, up from $12.9 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $22.2 million in Q4 2021 and troughed at $8.6 million in Q4 2019.
  • The 3-year median for Total Non-Current Liabilities is $11.6 million (2020), against an average of $12.5 million.
  • The largest YoY upside for Total Non-Current Liabilities was 91.02% in 2021 against a maximum downside of 9.17% in 2021.
  • A 3-year view of Total Non-Current Liabilities shows it stood at $8.6 million in 2019, then skyrocketed by 34.25% to $11.6 million in 2020, then skyrocketed by 91.02% to $22.2 million in 2021.
  • Per Business Quant, the three most recent readings for PLRX's Total Non-Current Liabilities are $22.2 million (Q4 2021), $12.9 million (Q3 2021), and $10.9 million (Q2 2021).